NRX Pharmaceuticals Inc. Common Stock (NRXP)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Mr. Market is quoting NRx Pharmaceuticals at $2.70 as of 2026-10-13, giving this clinical-stage CNS biotech a market capitalization of $116.9M. The business is not yet proven. In fiscal 2023, the year ended 2023-12-31, revenue was N/A and net loss was $30.1M. In fiscal 2024, the year ended 2024-12-31, revenue was N/A and net loss was $25.1M. In fiscal 2025, the year ended 2025-12-31, revenue was only $1.2M, while net loss was $28.6M. The latest filed quarter, fiscal Q2 2026, ended 2026-06-30, showed $1.1M revenue but a $16.5M net loss, or diluted EPS of -$0.44. Fiscal Q1 2026, ended 2026-03-31, had $1.1M revenue and a smaller $1.4M net loss, so results are uneven. From a Graham standpoint, there is no margin of safety in earnings or assets: at the $2.70 close on 2026-10-13, FairStock calculations show P/E of -4.66, P/B N/A, ROCE -63.99%, Piotroski 3/9, Altman Z-Score -12.03, and a FairStock Score of 34/100. Free cash flow is -$20.7M trailing twelve months, a -17.7% FCF yield. The moat, if any, rests on intellectual property and clinical success for NRX-101 and NRX-100, not on current commercial strength. The Peter Lynch category is none because it lost money in each of the last four years. Growth is a binary option on trials. I can admire the unmet need in suicidal depression, PTSD, and schizophrenia, but I cannot call this a sound value investment at present; the price is a speculative claim on future approvals, not a bargain backed by present profits.

In plain English: NRx Pharmaceuticals is a small biotech trying to develop medicines for mental-health conditions like severe depression and schizophrenia. It has almost no revenue and has lost money every recent year, so the underlying business looks weak. At $2.70, the price reflects hopes for future drugs rather than the profits it makes today.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer